CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

Autor: Bruce K. Patterson, Harish Seethamraju, Kush Dhody, Michael J. Corley, Kazem Kazempour, Jay Lalezari, Alina P.S. Pang, Christopher Sugai, Eisa Mahyari, Edgar B. Francisco, Amruta Pise, Hallison Rodrigues, Helen L. Wu, Gabriela M. Webb, Byung S. Park, Scott Kelly, Nader Pourhassan, Alina Lelic, Lama Kdouh, Monica Herrera, Eric Hall, Benjamin N. Bimber, Matthew Plassmeyer, Raavi Gupta, Oral Alpan, Jane A. O’Halloran, Philip A. Mudd, Enver Akalin, Lishomwa C. Ndhlovu, Jonah B. Sacha

Publikováno v: International Journal of Infectious Diseases, Vol 103, Iss , Pp 25-32 (2021)

Objective: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic. Emerging results indicate a dysregulated immune response. Given the role of CCR5 in immune cell migration and inflammation, we investigat

Externí odkaz: https://doaj.org/article/aa64df75735341c59242e660d8c57951

Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab

Autor: Nicholas Agresti, Jacob P. Lalezari, Phillip P. Amodeo, Kabir Mody, Steven F. Mosher, Harish Seethamraju, Scott A. Kelly, Nader Z. Pourhassan, C. David Sudduth, Christopher Bovinet, Ahmed E. ElSharkawi, Bruce K. Patterson, Reejis Stephen, Jonah B. Sacha, Helen L. Wu, Seth A. Gross, Kush Dhody

Publikováno v: Journal of Translational Autoimmunity, Vol 4, Iss , Pp 100083- (2021)

Coronavirus disease 2019 (COVID-19) is associated with considerable morbidity and mortality. The number of confirmed cases of infection with SARS-CoV-2, the virus causing COVID-19 continues to escalate with over 70 million confirmed cases and over 1.

Externí odkaz: https://doaj.org/article/390ffb01517147668c69e13a6b1b62e2

Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab

Autor: Kush Dhody, Otto O. Yang, Bryant Yang, Jonathan Fulcher, Arash Naeim, David Goodman-Meza, Jenny Ahn, Marlene Berro, Jonah B. Sacha

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol 73, iss 11
Clinical Infectious Diseases

Background Leronlimab, a monoclonal antibody blocker of C-C chemokine receptor type 5 originally developed to treat human immunodeficiency virus infection, was administered as an open-label compassionate-use therapeutic for coronavirus disease 2019 (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cab35acabc55619cb780dc0173cd883
https://escholarship.org/uc/item/2jd7n7z9

CCR5 Inhibition in Critical COVID-19 Patients Decreases Inflammatory Cytokines, Increases CD8 T-Cells, and Decreases SARS-CoV2 RNA in Plasma by Day 14

Autor: Enver Akalin, Jane A. O’Halloran, Edgar B. Francisco, Byung Park, Hallison Rodrigues, Eisa Mahyari, Philip A. Mudd, Bruce K. Patterson, Kush Dhody, Helen L. Wu, Nader Pourhassan, Alina P.S. Pang, Scott Kelly, Michael J. Corley, Jonah B. Sacha, Monica Herrera, Alina Lelic, Jay Lalezari, Amruta Pise, Eric W. Hall, Kazem Kazempour, Gabriela M. Webb, Lishomwa C. Ndhlovu, Lama Kdouh, Oral Alpan, Christopher Sugai, Harish Seethamraju, Benjamin N. Bimber, Matthew Plassmeyer, Raavi Gupta

Publikováno v: International Journal of Infectious Diseases
International Journal of Infectious Diseases, Vol 103, Iss, Pp 25-32 (2021)

Highlights • Treatment with the anti-CCR5 humanized monoclonal antibody restored depressed CD8 counts which inversely correlated with decreases in plasma viral load (pVL) which went to undetectable by Day 14 of treatment. • CCL5/RANTES is elevate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df32f48619ac21572737b1b2e9bb5250
http://europepmc.org/articles/PMC7654230

PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection

Autor: Derry Green, Denis Burger, Hana Mekonnen, Kazem Kazempour, Nader Pourhassan, Shide Badri, Paul J Maddon, Kush Dhody

Publikováno v: HIV clinical trials. 19(3)

Background PRO 140 is a humanized monoclonal antibody targeting CCR5 with potent antiviral activity in patients with CCR5-tropic HIV-1 infection. In phase 2b studies, we evaluated the long-term efficacy, safety, and tolerability of PRO 140 monotherap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1c88e03e781e46667a96261c358b049
https://pubmed.ncbi.nlm.nih.gov/29676212